CRYOPRESERVATION OF ALLOGENEIC HPC, MARROW PRODUCTS

It is essential for patient safety and product quality control that facilities performing cryopreservation of allogeneic marrow products do so using validated procedures and trained personnel. In these challenging times, AABB is aware that some programs, that do not yet have these measures in place, may be asked to cryopreserve unrelated allogeneic products to ensure the product is on hand before the recipient begins myeloablative therapy. The following list of AABB CT Section Coordinating Committee volunteers have offered to serve as a technical resource for these procedures and may be available to assist with the procedure, including red cell reduction. Please contact them directly, or any other technical experts, BEFORE you collect and receive the product, if you require assistance.

Thomas Spitzer, MD
Director, Cellular Therapy and Transplantation Laboratory
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, MA
tspitzer@mgh.harvard.edu

Federico Rodriguez Quezada SBB, MLSi(ASCP)CM
Stem Cell Lab Coordinator
Interim BMT Program Quality Manager
UF Health Shands Cancer Hospital
Gainesville, FL 32608
frod0001@shands.ufl.edu

AABB is providing this list as a resource to the community and is deeply appreciative of those who have generously offered their expertise and experience. Any arrangements for advice or services is strictly between the professionals and the program. AABB neither endorses nor warrants any services provided and expressly disclaims any liability for any damage or loss, whatsoever, that may arise from relying upon or using any of these professionals.

THE FOLLOWING REFERENCES MAY ALSO BE USEFUL RESOURCES:

AABB Publications

- Practical Handbook of Cellular Therapy Cryopreservation
- Cellular Therapy: Principles, Methods, and Regulations, 2nd edition